Better than Pfizer bosutinib Novartic Leukemia Oral Therapy Phase 3 clinical reached the main endpoint.
exposure, 17 new class 1 drugs bright eyes, 22 over-rated varieties over the screen.
Employee medical insurance will welcome 3 major changes Personal accounts are intended to be available to family members.
Johnson and Johnson's new crown vaccine announces the latest positive developments this month will begin phase 3 trials.
PD-1 antibody "new partner" - HDAC2 inhibitor.
Jiangsu sampling architectural coatings, such as Jieya 3 batches of products are not qualified.
Rare pediatric epilepsy new drug! Fintepla (Finteplamin) Treatment of Dravet Syndrome Phase 3 Phase
NEJM: Phase 1-2 clinical trials have shown that the NVX-CoV2373 candidate vaccine is safe and induces a strong immune response.
function decline in asthma patients: the efficacy is maintained for 3 years!
for children aged 6-11 years has been successful in Phase 3 research!
The first in China! Junshi Bio-Anti-PD-1 Therapy Ripley Monoanti (Toyi ®) has been recognized
The results of Jiangsu's third round of volume purchase will be implemented from October 1.
20 years of great innovation! Lilly 5-HT1F Agonist Reyvow New Phase III Study: Take the drug for 1 hour and the pain disappears for 48 hours!
Chronic nasal-sinusitis with new drugs for nasal psychics (CRSwNP)! AstraZeneta Fasenra (Benali Pearl Monomass) Phase 3 clinical success!
The first 癀 class 1 new drug approved clinical sword refers to solid tumors.
Parkinson's gene therapy! 3 years after NBIb-1817 one-time drug: Continuously shorten OFF time/extend ON time, improve sports function!
Qilu, Yangzijiang...... 75 new drugs approved clinically! Zhengda Sunny into 8 billion varieties, domestic 1 class of new drugs pile declaration.
Domestic PD-1 first half results are very public! It is expected to exceed 7 billion yuan for the full year.
for thyset migraines in adults: a double-blind, randomized phase 2b/3 trial.
The lowest unit price of Chinese medicine collection entered the era of 1 cent.